Advertisement
Canada markets closed
  • S&P/TSX

    22,167.03
    +59.95 (+0.27%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CAD/USD

    0.7379
    -0.0007 (-0.10%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • Bitcoin CAD

    94,662.18
    -1,001.23 (-1.05%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • RUSSELL 2000

    2,124.55
    +10.20 (+0.48%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • NASDAQ

    16,379.46
    -20.06 (-0.12%)
     
  • VOLATILITY

    13.01
    0.00 (0.00%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • CAD/EUR

    0.6847
    +0.0004 (+0.06%)
     

Today’s Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Gilead Sciences

NEW YORK, NY / ACCESSWIRE / February 12, 2018 / U.S. markets managed to finish in the green on Friday, despite concerns of rising interest rates and inflationary pressure. The Dow Jones Industrial Average jumped 1.38 percent to close at 24,190.90, while the S&P 500 Index increased 1.49 percent to close at 2,619.55. The Nasdaq Composite Index increased 1.44 percent to close at 6,874.49. The Cboe Volatility Index, a key measure of market expectations of near-term volatility, reached a high of 41.06 on Friday, before settling at 29.06.

According to Richard Hastings, a macro strategist at Seaport Global Securities LLC, "The bull market is not over. It is getting a new and better price, so it can go higher all over again. The relationship of the price—of many stocks—to their own yields and to interest rates, all went into chaos. Order is being restored."

RDI Initiates Coverage on:

Regeneron Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=REGN

ADVERTISEMENT

Gilead Sciences, Inc.
https://rdinvesting.com/news/?ticker=GILD

Regeneron Pharmaceuticals' stock moved 4.27% higher Friday, to close the day at $336.38. The stock recorded a trading volume of 2,088,286 shares, which was above its three months average volume of 919,278 shares. In the last year, Regeneron Pharmaceuticals' shares have traded in a range of 314.99 - 543.55. The stock is currently trading 38.11% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $368.72 is below its 200-day moving average of $418.24. Shares of Regeneron Pharmaceuticals are trading at a trailing Price to Earnings ratio of 32.53. Shares of Regeneron Pharmaceuticals have fallen roughly 8.66 percent in the past month and are down 10.53 percent year-to-date.

Access RDI's Regeneron Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=REGN

On Friday, shares of Gilead Sciences recorded a trading volume of 13,746,392 shares, which was above the three months average volume of 8,778,503 shares. The stock ended the day 1.41% higher at 79.32. The stock is currently trading 11.41% below its 52-week high with a 52-week trading range of 70.05 - 89.54. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $79.22 is greater than its 200-day moving average of $76.65. Shares of the company are trading at a trailing Price to Earnings ratio of 22.60. Shares of Gilead Sciences have gained roughly 0.33 percent in the past month and are up 10.72 percent year-to-date.

Access RDI's Gilead Sciences, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=GILD

Our Actionable Research on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Gilead Sciences, Inc. (NASDAQ:GILD) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com